SUMMARY Sodium nitroprusside (NP) is a potent vasodilator that also inhibits platelet aggregation. To test the hypothesis that NP causes both of these effects by altering the balance between prostacyclin (PGI2) produced by endothelial cells and thromboxane A2 (TXA2) produced by platelets, we incubated each of these cell types with NP for 5 minutes and assayed the PGI2 and TXA2 produced. NP at pharmacologically achieved doses (0.01-30 ,ug/ml) inhibited platelet aggregation and resultant TXA2 synthesis in a dose-and time-dependent manner (p < 0.001). The inhibition was not dependent on cAMP production, external calcium concentration, or suppression of TXA2 synthesis. NP did not alter the production of PGI2 by cultured human endothelial cells as measured by radioimmunoassay for 6-Keto-PGFa, the stable hydrolysis product of PGI2. However, supernates of NP-treated endothelial cells containing low, noninhibitory concentrations of NP unexpectedly inhibited platelet aggregation. This inhibition. of platelet aggregation was due to synergy between PGI2 (0.1-3 nM) and NP (p interaction < 0.003). The synergistic inhibition by NP and PGI2 of platelet aggregation and TXA2 synthesis in vivo may explain some of the beneficial actions of NP in the treatment of hypertension and congestive heart failure.
SODIUM NITROPRUSSIDE (NP) is a vasodilator widely used to treat hypertensive crises and congestive heart failure complicating myocardial ischemia. It is one of a group of vasodilators that includes nitroglycerin, dipyridamole, verapamil and hydralazine, which also inhibit platelet aggregation in vitro. -7 NP also inhibits the formation of platelet aggregates in vivo, and part of its beneficial effect may result from this inhibition. We recently demonstrated that nitroglycerin induces human endothelial cells in tissue culture to synthesize prostacyclin (PG12),7 a potent, naturally occurring vasodilator and platelet inhibitor.9' 10 The PG12 produced by these endothelial cells inhibits platelet aggregation in vitro. To explore the hypothesis that NP modulates vascular tone and relieves ischemia by shifting the ratio of PGI, to thromboxane A2 (TXA2) in the circulation toward PG12 excess, we studied the effect of NP on endothelial cells and platelets.
Methods Platelet Aggregation and Thromboxane B2 Production Platelet-rich plasma (PRP) was prepared from venous blood and platelet counts were determined on a model ZBI Coulter counter by methods described. " Aggregation was induced with the following aggregating agents (expressed as final concentration in the cuvette): sodium arachidonate (Nu Chek), 0.1-3 mM; fibrillar bovine collagen (Hormon-Chemie), 0.6-1. 6 jig/ml; and epinephrine (Parke Davis), 2-4.3 ,uM.
Platelet aggregation was performed in a dual-channel aggregometer (Payton Associates) as previously described. "I In brief, light transmission through PRP was set at 0% and through platelet-poor plasma at 100%. The threshold aggregating concentration of each agent was determined after incubating the PRP for 1-5 minutes with buffer I such that the final volume after all additions was 0.5 ml. Threshold aggregation was then defined as the lowest concentration of an agent that caused at least a 90% increase in light transmission at 5 minutes when added to PRP maintained at 37°C and stirred at a constant rate of 1000 rpm.
Aggregation of platelets may be quantitated by measuring any of the characteristics of the curve of increasing light transmission generated as the platelets aggregate. These include measurement of the lag phase after addition of the stimulus and before the onset of aggregation, the initial slope of the curve, the maximal increase in light transmission, or In each experiment, platelet-poor plasma was prepared by centrifuging blood, from which PRP had been removed, at 8500 g for 5 minutes. Controls for TXB, measurement were prepared by incubating plateletpoor plasma in aggregation cuvettes in a manner identical to that for PRP. Aliquots of each aggregating agent and inhibitor alone and in combination were then incubated in the cuvette containing platelet-poor plasma for 5 minutes and processed as described above. These controls were used to verify that none of the agents added to PRP interfered with the RIA for TXB,. Samples of PRP incubated for 5 minutes without additions other than buffer were also prepared to determine background TXB2 levels. were all less than 0.1%.
Because of the presence of human serum in samples assayed for TXB2 by radioimmunoassay, a doubleantibody technique using goat antirabbit IgG bound to beads (Immunobead second antibody, Bio-Rad Laboratories) was used. The TXB2 RIA using 3H TXB2 (New England Nuclear, 150 Ci/mmol) and antisera at 1:4800 was otherwise performed in the same way as the 6-Keto-PGFla RIA described above. The range of sensitivity for TXB2 was 3-1000 pg with 50% binding at 30-40 pg. Cross reactivities were as follows: PGF2I 0.6%; PGE2, 0.06%; PGF2a9 0.5%; PGE,, 0.2%; 6-Keto-PGF,a and 6-Keto-PGEp, < 0.02%; 6,15-diketo-PGFta and 13,14 dihydro 6,15-diketo-PGF1,, < 0.02%.
Mechanism of Nitroprusside Inhibition of Platelet Aggregation
A series of platelet aggregation experiments was performed to determine the role of several platelet systems or constituents in the mediation of NP inhibition of platelet aggregation.
Thromboxane A2
PRP was prepared from donors who had ingested 650 mg of aspirin within 24 hours before the experiment. Complete inhibition of platelet TXA2 synthesis was inferred by demonstrating the absence of aggregation in response to sodium arachidonate at any concentration. PRP was stimulated with 11l-,M epinephrine, which yielded a stable primary wave of aggregation with a 20% increase in light transmission. The output to the recorder was then adjusted such that this 20% increase yielded a deflection of 10 cm. Thus, aggregation could then be quantitated as described above. The dose-response to NP was then determined and compared with the same donor's response to NP in a control state when no aspirin had been ingested.
Calcium
Experiments were performed in which the ionized calcium concentration in PRP was varied. Blood from single donors was drawn either into 1/10 volume of Hepes-buffered saline containing sodium heparin, 50 U/ml (Upjohn Co.), which does not alter the ionized calcium concentration of plasma,20'21 or into 1/10 volume of 3.2% sodium citrate containing sodium heparin, 50 U/ml. Sodium citrate at a final concentration of 0. 32% as obtained in these experiments lowers plasma ionized calcium concentration from the normal level of approximately 1 mM to 0.04 mAM, a 25-fold decrease.2' PRP was then prepared as described above. Aggregation was simultaneously induced by collagen (0.8-1.6 ,ug/ml) in both heparin and heparin-citrated PRP in an autostandardizing, dual-channel aggregometer (model 600, Payton Associates) after a 1-minute incubation with either buffer I alone or NP (0-3 gg/ ml). Inhibition of aggregation by NP as a function of calcium concentration was then determined by comparing the amount of inhibition induced by the varying concentrations of NP in both the heparin (normal calcium) and heparin-citrated (low calcium) PRP.
cAMP
Platelet adenylate cyclase was inhibited by incubating PRP with 2'5' dideoxyadenosine (DDA) (P-L Biochemicals), final concentration 100 ,uM, for 1-2 minutes at 370C.22 23 The activity of DDA was verified by demonstrating that 100 ,uM DDA abolished the inhibition of aggregation induced by PGI2 (1-10 nM), which is known to inhibit platelet aggregation by inducing a rise in platelet cAMP.2F26 After incubation with DDA, threshold aggregation was induced as described above, and the inhibition of aggregation by NP (0.1-1O ,ug/ ml) was determined.
Microtubule Agents
The effect of NP on platelet aggregation was determined in the presence of the microtubule stabilizer deuterium oxide (D20, Sigma Chemical Co.) and the microtubule disrupter colchicine (Sigma Chemical Co.).27-29 For experiments with D20, PRP was prepared and then diluted with buffer I enriched with D20 (0-100%) such that final concentrations of D20 in PRP were 0-60%. Platelet counts after all dilutions were not less than 150,000/jul. In experiments using colchicine, PRP was incubated in the aggregation cuvette for 1-2 minutes with colchicine (0.15-1 mM) before addition of a threshold stimulus. To determine whether NP induces endothelial cells to synthesize PGI2 we incubated monolayer cultures of human umbilical vein endothelial cells with NP (0.0 1-30 ,ug/ml) for 5 minutes and analyzed the supernates by RIA for 6-Keto-PGFia, the stable hydrolysis product of PGI2. There were no significant differences in the amounts of PGI2 produced by endothelial cells whether incubated with NP or buffer alone (p > 0.20, one-way ANOVA, data not shown). Sodium arachidonate and thrombin, both of which stimulate endothelial cell PG12 production, were used in wells of each plate as positive controls. Both agents induced a fourfold to 20-fold increase in PGI2 production compared with the buffer control, which verified that the cells could metabolize exogenous or endogenous arachidonic acid to PGI1.
To determine whether NP might alter the production of endothelial cell PGI2 in response to other agents, endothelial cells were treated with either thrombin (0.1 U/ml) or sodium arachidonate (20 aggregation other than PGI2, or NP and PGI2 acted synergistically to inhibit platelet aggregation. The first possibility was studied by pretreating endothelial cells with the cylcooxygenase inhibitor aspirin, 50 ,M, for 2 hours,'7 or the prostacyclin synthetase inhibitor 15-hydroperoxyarachidonic acid, 5-20 Zgl ml, for 30 minutes. 18 Both of these agents almost completely inhibited PGI2 production by endothelial cells as verified by RIA; supernates of NP-treated endothelial cells pretreated with either of these agents did not inhibit platelet aggregation (data not shown). Furthermore, when an active supernate was incubated at 37°C for 5 minutes, the activity was abolished. This decay rate is consistent with the decay of the biologic activity of PGI2. Therefore, the presence of PGI2 in the supernate was necessary, but insufficient alone, to inhibit platelet aggregation ( fig. 2 ). This finding suggested that both PGI and NP were necessary to inhibit platelet aggregation at the concentrations tested.
To demonstrate that NP and PGI2 synergistically inhibit platelet aggregation and TXA2 synthesis, we preincubated various concentrations of NP alone, synthetic PGI2 alone, and combinations of NP and PGI2
with PRP for 1 minute before stimulation with threshold doses of epinephrine. The data in tables 1 and 2 
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show that when NP and PGI2 are combined, the resultant inhibition of platelet aggregation and TXA2 synthesis is much greater than the sum of the inhibitions generated by each agent alone; this type of result defines synergistic inhibition. These interactions (synergies) are highly significant (p < 0.0001 and p < 0.0004, respectively, two-way ANOVA). Similar results were obtained with collagen and arachidonate as aggregating agents (data not shown).
Mechanism of Nitroprusside's Inhibition of Platelet Aggregation
To explore the mechanism of NP-PGJ2 synergy in inhibiting platelet aggregation, we examined four possible mechanisms of NP inhibition of platelet aggregation: direct inhibition of TXA2 synthesis, inhibition of transmembrane calcium movement, elevation of platelet cAMP, and interaction with platelet microtubules.
Thomboxane A2 Inhibition
The experiments shown in figure 1 suggested that NP did not inhibit platelet aggregation by directly inhibiting TXA2 synthesis. Depending on the aggregating agent, similar inhibitions of aggregation occurred despite markedly different extents of inhibition of TXA2 synthesis. To study this further, NP was incubated with aspirin-treated platelets and primary-wave aggregation was induced with epinephrine. This TXA2-independent aggregation was significantly inhibited by NP at concentations identical to those used in normal platelets (IC50 -3 /g/ml NP, p < 0.0001). RIA for TXB2 confirmed that no TXA2 had been synthesized.
Thus, in the absence of TXA2, NP inhibited primary aggregation in aspirin-treated platelets in a manner equivalent to the inhibition of full aggregation in nonaspirin-treated platelets. Therefore, it is unlikely that NP inhibits aggregation by suppressing platelet TXA, synthesis directly.
Calcium
Calcium-45 flux experiments in other systems have suggested that NP does not act as a muscle relaxant by inhibiting transmembrane calcium movement.3"-We explored the role of calcium indirectly by studying the inhibitory effect of varying doses of NP on platelet aggregation induced by collagen (0.8-1.6 ,ug/ml) in both normocalcemic, heparinized PRP and hypocalcemic, heparinized-citrated PRP. As in previous experiments, NP inhibited platelet aggregation (PNP < 0.0001, two-way ANOVA). Lowering the ionized calcium concentration from the normal level of approximately 1 mM to approximately 0.04 mM with 0.32% sodium citrate20 21 caused a significant decrease in the extent of aggregation (Pca < 0.0001, two-way ANOVA). However, there was no interaction between calcium and NP in inhibiting aggregation (data not shown, Psnyery K< 0.40, two-way ANOVA), which suggests that NP does not inhibit platelet aggregation by altering calcium flux through the platelet membrane.
cAMP Inhibitors of platelet function such as PGJ2 act by causing an elevation of platelet cAMP, which in turn inhibits aggregation.2>26 The adenosine analog 2',5'-dideoxyadenosine is a specific inhibitor of adenylate cyclase, which abolishes both the elevation of platelet cAMP induced by PGI2 and the subsequent inhibition of platelet aggregation.34 Incubation of PRP with 100 ,M dideoxyadenosine almost completely abolishes PGI2-mediated inhibition of epinephrine-induced platelet aggregation, but does not change the NP-mediated inhibition of platelet aggregation ( fig. 3 ). This lack of effect was demonstrated at multiple concentrations of NP. Similar results were obtained when collagen was the aggregating agent. Thus, NP does not inhibit platelet aggregation by causing an elevation in platelet cAMP.
Colchicine and Deuterium Oxide
Colchicine disrupts the equilibrium between tubulin dimers and assembled microtubules and favors microtubule disruption,28 which in turn inhibits platelet aggregation.35 36 D20 stabilizes microtubule formation27 29 and enhances platelet aggregation.37 If NP interacts with microtubules, the inhibition of platelet aggregation induced by NP should be synergistically altered by preincubation of PRP with either colchicine or D20. Figure 4 shows that D20 and colchicine alter the inhibition by NP of collagen-induced platelet ag- Discussion In this study, NP inhibited both platelet aggregation and the resultant TXA2 synthesis in a dose-and timedependent manner. Further, while NP did not stimulate endothelial cells to synthesize PGI2, NP and PGI2 synergistically inhibited both platelet aggregation and TXA2 synthesis. The inhibition of platelet aggregation induced by supernates of NP-treated endothelial cells was dependent on this synergy, because pretreating the endothelial cells with either aspirin or 15-hydroperoxy arachidonic acid blocked both the background production of PGI as measured by RIA and the inhibition of platelet aggregation. This finding does not absolutely rule out the presence of additional endothelial cell metabolites, such as adenosine,38 that inhibit platelet aggregation. However, adenosine release is not affected by aspirin treatment, and adenosine is only slowly produced from ATP released by endothelial cells;39 40 thus, only small amounts of adenosine would be present after the 5-minute incubation used in our experiments. Furthermore, the activity of the supernate is heat labile and adenosine is not. Thus, although other metabolites may contribute to the inhibition of platelet aggregation by supernates of NP-treated cells, our studies demonstrate that synergy is absolutely dependent on PGJ2 and NP and can be produced in vitro using only synthetic PGI2 and NP alone.
The concentration of NP in which these phenomena were noted was 0.01-30 ,ug/ml. Although the lowest concentration of NP that directly inhibited arachidonate-induced platelet aggregation and TXA2 synthesis was 0.1 g/ml, the lowest concentration at which synergy for these inhibitions was detected was 0.01 ,ug/ ml. These concentrations of NP We demonstrated a significant interaction between NP and the microtubule agents colchicine and D20.
Microtubule function has an important role in platelet activation.3 D20, a microtubule stabilizer,27 29 synergistically diminished the effect of NP, whereas colchicine, a microtubule disrupter,28 synergistically enhanced NP inhibition of platelet aggregation. The combination of colchicine and PGI2, however, also synergistically inhibited platelet aggregation; therefore, our studies do not prove that NP inhibits microtubule function. Further studies will be needed to determine whether these synergistic interactions are due to a direct effect on microtubules or indicate simply that microtubule function is a common element in the effector pathway for platelet aggregation.
The clinical relevance of the interaction between vasodilators and platelet and endothelial cell prostaglandin production lies in the growing recognition that platelet aggregation may contribute to such ischemic events as angina and myocardial infarction.55 Both experimental and clinical observations, indicate that platelet aggregates form at narrowed and eroded areas of atherosclerotic plaques and result in transient obstruction of the circulation. If unrelieved, such obstruction may result in an occlusive thrombosis and concomitant infarction.58 The platelet aggregates may also release TXA2 and cause local vasoconstriction, which will further limit flow, and may also cause endothelial disruption,57 which will lead to increased platelet activation. If this hypothetical framework is correct, vasodilators may be beneficial not only beause they reduce preload and afterload, but also because they interrupt the cycle of platelet aggregation, TXA, synthesis and vascular spasm.
